HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Homotypic gap junctional communication associated with metastasis suppression increases with PKA activity and is unaffected by PI3K inhibition.

Abstract
Loss of gap junctional intercellular communication (GJIC) between cancer cells is a common characteristic of malignant transformation. This communication is mediated by connexin proteins that make up the functional units of gap junctions. Connexins are highly regulated at the protein level and phosphorylation events play a key role in their trafficking and degradation. The metastasis suppressor breast cancer metastasis suppressor 1 (BRMS1) upregulates GJIC and decreases phosphoinositide-3-kinase (PI3K) signaling. On the basis of these observations, we set out to determine whether there was a link between PI3K and GJIC in tumorigenic and metastatic cell lines. Treatment of cells with the well-known PI3K inhibitor LY294002, and its structural analogue LY303511, which does not inhibit PI3K, increased homotypic GJIC; however, we found the effect to be independent of PI3K/AKT inhibition. We show in multiple cancer cell lines of varying metastatic capability that GJIC can be restored without enforced expression of a connexin gene. In addition, while levels of connexin 43 remained unchanged, its relocalization from the cytosol to the plasma membrane was observed. Both LY294002 and LY303511 increased the activity of protein kinase A (PKA). Moreover, PKA blockade by the small molecule inhibitor H89 decreased the LY294002/LY303511-mediated increase in GJIC. Collectively, our findings show a connection between PKA activity and GJIC mediated by PI3K-independent mechanisms of LY294002 and LY303511. Manipulation of these signaling pathways could prove useful for antimetastatic therapy.
AuthorsThomas M Bodenstine, Kedar S Vaidya, Aimen Ismail, Benjamin H Beck, Leah M Cook, Anne R Diers, Aimee Landar, Danny R Welch
JournalCancer research (Cancer Res) Vol. 70 Issue 23 Pg. 10002-11 (Dec 01 2010) ISSN: 1538-7445 [Electronic] United States
PMID21098703 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
Chemical References
  • Androstadienes
  • Chromones
  • Connexin 43
  • Enzyme Inhibitors
  • Fluoresceins
  • Isoquinolines
  • Morpholines
  • Phosphoinositide-3 Kinase Inhibitors
  • Piperazines
  • Sulfonamides
  • LY 303511
  • 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
  • Proto-Oncogene Proteins c-akt
  • Cyclic AMP-Dependent Protein Kinases
  • N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide
  • fluorexon
  • Wortmannin
Topics
  • Androstadienes (pharmacology)
  • Cell Communication
  • Cell Line, Tumor
  • Cell Membrane (metabolism)
  • Chromones (pharmacology)
  • Connexin 43 (metabolism)
  • Cyclic AMP-Dependent Protein Kinases (antagonists & inhibitors, metabolism)
  • Cytosol (metabolism)
  • Enzyme Activation (drug effects)
  • Enzyme Inhibitors (pharmacology)
  • Fluoresceins (metabolism)
  • Fluorescent Antibody Technique
  • Gap Junctions (drug effects, metabolism)
  • Humans
  • Immunoblotting
  • Isoquinolines (pharmacology)
  • Morpholines (pharmacology)
  • Neoplasm Metastasis
  • Neoplasms (metabolism, pathology)
  • Phosphatidylinositol 3-Kinases (metabolism)
  • Phosphoinositide-3 Kinase Inhibitors
  • Phosphorylation (drug effects)
  • Piperazines (pharmacology)
  • Proto-Oncogene Proteins c-akt (antagonists & inhibitors, metabolism)
  • Signal Transduction (drug effects)
  • Sulfonamides (pharmacology)
  • Wortmannin

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: